The clinical development programs at MAP Pharmaceuticals include proprietary product candidates that address large market opportunities. The most advanced product candidate is LEVADEX™ orally inhaled migraine therapy, currently in Phase 3 clinical development.
In addition to our migraine program, our development portfolio includes drug candidates for the treatment of asthma, chronic obstructive pulmonary disease (COPD), and diabetes, as well as therapeutics for other disorders that could benefit from pulmonary delivery.
